Alzamend Neuro Inc (ALZN)

Jun 14, 2026

ALZN Q1 2026 Earnings: Smaller-than-Expected Loss Drives Shares HigherEarnings Manipulation Risk - newsline.com

Jun 14, 2026

Jun 10, 2026

Alzamend Neuro, Inc. Financial Disclosures & SEC Filings - TradingView

Jun 10, 2026

Jun 08, 2026

ALZN Q1 2026 Earnings: Narrower-than-Expected Loss Delivers 70% Positive SurpriseEarnings Revision Downgrade - newsline.com

Jun 08, 2026

Jun 04, 2026

Alzamend Neuro Shares Dip With AL001 Trial in Focus, Cash Concerns Linger - Bez Kabli

Jun 04, 2026

Jun 04, 2026

ALZN Q1 2026 Earnings: Significant EPS Beat Driven by Narrower-than-Expected LossOne-Time Loss Impact - newsline.com

Jun 04, 2026

May 29, 2026

Alzamend Neuro, Inc.Common Stock (NQ: ALZN - FinancialContent

May 29, 2026

May 29, 2026

Alzamend Neuro (ALZN) Gains 3.48% as Positive Momentum BuildsCash Secured Put - newsline.com

May 29, 2026

May 28, 2026

ALZN Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost Management Amid Pre-Revenue PhaseSaaS Earnings Trends - The Legal Advocate

May 28, 2026

May 27, 2026

Alzamend Neuro Inc. (ALZN) Stalls Near Support: Consolidation or Caution for This Alzheimer’s Play?Momentum Factor - thelegaladvocate.com

May 27, 2026

May 25, 2026

Alzamend Neuro Inc. (ALZN) Q1 2026 Earnings: Narrower-than-Expected Loss as Early-Stage Biotech Continues R&D FocusEarnings Quality Score - newsline.com

May 25, 2026

May 24, 2026

ALZN Q1 2026 Earnings: Narrowing Losses Beat Estimates by 70%EBITDA Estimate Trend - newsline.com

May 24, 2026

May 23, 2026

ALZN Q1 2026 Earnings: EPS Surpasses Estimates by Over 70%, Stock DeclinesEarnings Season Preview - The Legal Advocate

May 23, 2026

May 22, 2026

ALZN Stock Price, Quote & Chart | ALZAMEND NEURO INC (NASDAQ:ALZN) - ChartMill

May 22, 2026

May 13, 2026

TradingKey - TradingKey

May 13, 2026

May 08, 2026

How Alzamend (ALZN) handles its debt maturity schedule | Q1 2026: Earnings Beat EstimatesTop Analyst Buy Signals - newser.com

May 08, 2026

May 08, 2026

Alzamend Neuro Inc. (ALZN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

May 08, 2026

Apr 28, 2026

Alzamend Neuro (ALZN) price target decreased by 10.71% to 25.50 - MSN

Apr 28, 2026

Apr 20, 2026

Alzamend (ALZN) Stock Swing Trade Setup (On the Radar) 2026-04-20Sector Rotation - Cổng thông tin điện tử tỉnh Lào Cai

Apr 20, 2026

Apr 18, 2026

Alzamend Neuro, Inc. 8-K Filing Details, NASDAQ Listing, and Corporate Information (April 17, 2026) - Minichart

Apr 18, 2026

Apr 18, 2026

Alzamend Neuro Shareholders Approve Governance and Capital Measures - The Globe and Mail

Apr 18, 2026

Apr 17, 2026

Shareholders of Alzamend Neuro (ALZN) approve board slate, plans and reverse split - Stock Titan

Apr 17, 2026

Apr 16, 2026

Director Milton Ault adds Alzamend Neuro (ALZN) shares in open-market buy - Stock Titan

Apr 16, 2026

Apr 13, 2026

CEO Moves: How sensitive is Alzamend Neuro Inc to inflationEarnings Overview Report & Smart Investment Allocation Tips - baoquankhu1.vn

Apr 13, 2026

Apr 13, 2026

Form PRE 14AOther preliminary proxy statements - ADVFN

Apr 13, 2026

Apr 12, 2026

Can Alzamend Neuro Inc disrupt its industryEarnings Growth Summary & Weekly High Conviction Trade Ideas - baoquankhu1.vn

Apr 12, 2026

Apr 09, 2026

Aug Sectors: What is the dividend yield of Alzamend Neuro IncQuarterly Profit Review & Long-Term Safe Return Strategies - baoquankhu1.vn

Apr 09, 2026

Apr 08, 2026

Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE), Alzamend Neuro (ALZN) and Cardiol Therapeutics (CRDL) - The Globe and Mail

Apr 08, 2026

Apr 08, 2026

Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital - Sahm

Apr 08, 2026

Apr 07, 2026

In a 6-person study, new lithium therapy disturbed less brain chemistry - Stock Titan

Apr 07, 2026

Mar 31, 2026

Alzamend Neuro Stock Rockets On Dosing Of First Human Patient With Lithium-Delivery System AL001 In Phase II Study: Retail’s Thrilled - MSN

Mar 31, 2026

Mar 30, 2026

Hedge Fund Bets: Can Alzamend Neuro Inc disrupt its industryChart Signals & Consistent Income Trade Recommendations - baoquankhu1.vn

Mar 30, 2026

Mar 27, 2026

12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga

Mar 27, 2026

Mar 27, 2026

Alzamend’s AL001 meets bioequivalence in phase 2 brain trial By Investing.com - Investing.com Australia

Mar 27, 2026

Mar 26, 2026

Alzamend Neuro in Freefall: A 22% Plunge Shatters $1.93 as Panic Sets In - Bitget

Mar 26, 2026

Mar 26, 2026

Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions - Investing News Network

Mar 26, 2026

Mar 26, 2026

Alzamend’s AL001 meets bioequivalence in phase 2 brain trial - Investing.com

Mar 26, 2026

Mar 26, 2026

Across 26 brain regions, Alzamend’s lithium drug showed higher levels - Stock Titan

Mar 26, 2026

Mar 21, 2026

Alzamend Neuro Receives Nasdaq Notice Over Equity Deficiency - The Globe and Mail

Mar 21, 2026

Mar 21, 2026

Alzamend Neuro, Inc. Receives Nasdaq Delisting Notice: SEC Form 8-K Filing March 2026 - Minichart

Mar 21, 2026

Mar 20, 2026

Alzamend Neuro Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView

Mar 20, 2026

Mar 20, 2026

[8-K] Alzamend Neuro, Inc. Reports Material Event - Stock Titan

Mar 20, 2026

Mar 18, 2026

Exit Recap: How sensitive is Alzamend Neuro Inc to inflationEarnings Performance Report & Free Verified High Yield Trade Plans - baoquankhu1.vn

Mar 18, 2026

Mar 17, 2026

Quarterly Recap: Will PAVM outperform during market rallies2026 Price Momentum & Short-Term High Return Strategies - baoquankhu1.vn

Mar 17, 2026

Mar 17, 2026

Alzamend initiates phase II trial of AL001 in bipolar disorder By Investing.com - Investing.com South Africa

Mar 17, 2026